Department of Pathology and Laboratory Medicine, University of California, Irvine School of Medicine, Orange, California, USA.
J Clin Apher. 2022 Oct;37(5):512-515. doi: 10.1002/jca.22002. Epub 2022 Aug 23.
Efgartigimod represents a first-in-class immunomodulatory agent that is comparable to TPE in reducing immunoglobulin levels. This translates to reductions in Myasthenia Gravis symptom scores with maximal effect following the fourth weekly efgartigimod dose. Efgartigimod received FDA approval in December of 2021 and may be an alternative particularly for patients on long-term TPE regimens of weekly or less frequent. Apheresis practitioners, especially those managing long-term apheresis in seropositive individuals, may therefore see some of their patients transitioned from plasma exchange to efgartigimod. Long-term experience with efgartigimod remains lacking and studies are needed to establish the role of efgartigimod in the acute setting.
依库珠单抗是一种首创的免疫调节剂，其降低免疫球蛋白的作用与 TPE 相当。这可转化为肌无力症状评分的降低，且在第四周每周依库珠单抗剂量后达到最大效果。依库珠单抗于 2021 年 12 月获得 FDA 批准，对于长期每周或更不频繁 TPE 治疗方案的患者，可能是一种替代疗法。因此，血液科医生，尤其是管理血清阳性患者长期血液净化的医生，可能会看到一些患者从血浆置换转为依库珠单抗治疗。目前尚缺乏依库珠单抗的长期经验，需要研究来确定依库珠单抗在急性情况下的作用。
